Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Lorazepam · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Lorazepam Tablets 2 mg |
| 2 | ACTIVE_COMPARATOR | Ativan Tablets 2 mg |
| Name | Type | Description |
|---|---|---|
| Lorazepam Tablets 2 mg | DRUG | 2mg, single dose fasting |
| Ativan Tablets 2 mg | DRUG | 2mg, single dose fasting |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and non-pregnant, non-lactating female 1. Women of childbearing potential must have negative serum (Beta HCG) pregnancy tests performed within 14 days prior to the start of the study and on the evening prior to each dose administratio...
Lorazepam is a small molecule drug developed by Viatris Inc. (ticker VTRS) and is also known as Lorazepam Tablets 2 mg. It is a Phase 1 investigational product studied in healthy adult volunteers. Its therapeutic area is classified as Other, and the specific indications being pursued have not been disclosed.
Lorazepam targets GABA-A receptor subunits, specifically GABRA1, GABRB2, GABRG2, GABRB3, GABRA4, and GABRG3. It acts as a positive allosteric modulator at these receptor sites. This target class places it among compounds that enhance GABA-A receptor signaling.
Lorazepam is developed by Viatris Inc., which trades under the ticker VTRS. Viatris is the company associated with the Lorazepam Tablets 2 mg program. The drug is a small molecule and is also known by the name Lorazepam Tablets 2 mg.
Lorazepam is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The program has one completed Phase 1 trial, with no active trials currently listed. The single completed study enrolled 28 participants.
Lorazepam has been studied in one completed Phase 1 trial, NCT00649818, titled Fasting Study of Lorazepam Tablets 2 mg and Ativan Tablets 2 mg. The trial enrolled 28 healthy adult volunteers in the United States, used an active-controlled, randomized design, and included both male and female participants aged 18 years and older.